acelrx.com
Acelrx. Talphera is developing Niyad™, nafamostat, for patients undergoing renal replacement therapy.
Optimizing outcomes in medically supervised settings | Talphera
Acelrx.com is a moderately popular website, according to Alexa, which gave it an ordinary traffic rank. Moreover, Acelrx has yet to grow their social media reach, as it’s relatively low at the moment: 3 Google+ votes and 1 Twitter mention. There is still a lack of data on safety and reputation of this domain, so you should be very careful when browsing it.
Popular pages to visit on acelrx.com
Talphera is developing Niyad™, nafamostat, for renal replacement therapy in dialysis patients who cannot tolerate heparin or have an increased risk of bleeding
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain.
Advanced Alexa Stats
| Traffic Rank: | 785 853 | |
| Month Average Daily Reach: | 0.000008 | -58.2% |
| Month Average Daily Pageviews: | 0 | -58.2% |
Domain info
| Location: | United States |
| Owned by: | PERFECT PRIVACY, LLC |
| Hosted by: | Vultr Holdings, LLC |
| Registered by: | Register.com, Inc. |
| Subnetworks: | 149.28.220.224 |
More domains registered by Register.com, Inc.
Social Networks Activity
| Facebook likes: | - |
| Twitter mentions: | 1 |
| Google pluses: | 3 |
| LinkedIn mentions: | - |
| Pinterest pins: | - |
| StumbleUpon views: | - |
